BridgeBio Pharma BBIO
United StatesHealthcare · BiotechnologyUSD
109.05 USD (+64.0%)
21 analysts
Trading 2120.30 €Open account ↗
Lightyear0.90 €Open account ↗
N260.90 €Open account ↗
XTB1.00 €★ featured · affiliateOpen account ↗Trading 2120.30 €Open account ↗Lightyear0.90 €Open account ↗XTB1.00 €★ featured · affiliateOpen account ↗200.00 € order · cheapest cheapest available in your country iCompare all 22 brokers →What does it do?
BridgeBio Pharma is a commercial-stage biopharmaceutical company that develops and commercializes innovative therapies for genetic and oncological diseases with unmet medical needs.
Key points
from its scores- ✓Strong growth10.0
- ✓High-quality business9.5
- ✕Little or no dividend0.5
- ✕Demanding valuation0.6
- !Risks to watch5.9
AI analysis
bottom line, main risk, context and newsHold in the portfolio only for investors with high risk tolerance and a long-term horizon; the current valuation discounts commercial success that is not yet reflected in earnings.
BridgeBio shows exceptional revenue growth (120.40%) and a very high gross margin (94.44%), but it remains unprofitable (operating margin of -43.94%) and its valuation is extremely demanding (forward P/E of 2301.04), making it vulnerable to a rising rate environment.
The main risk is regulatory: dependence on FDA approvals for its pipeline drugs, whose failure or delay could sink the company's valuation.
Context and risks
BridgeBio operates in the US biotechnology sector, where regulatory risk is inherent: FDA approval is a binary event that can determine the company's value. Furthermore, the company does not generate profits and its valuation depends on distant future cash flows, making it sensitive to a rising interest rate environment that pressures long-duration multiples.
Is BridgeBio Pharma stock cheap or expensive?
at the analysis dateOn Price / sales, it trades 434% above the Healthcare median.
| Multiple | Company | Sector | Difference |
|---|---|---|---|
| Price / sales | 18.2 | 3.4 | +434% |
Sector: median of the 217 Healthcare companies analysed. In bold, the multiples used for the comparison.
Valuation score: 0.6 out of 10 (median for Healthcare: 4.7).
Average analyst target: 109.05 USD, +64.0% versus the price.
A premium can be justified if the company is of higher quality or grows faster than its sector: Quality / Moat 9.5 (sector 5.5), Growth 10.0 (sector 6.6).
Work out its fair value yourself →How much would you have made investing every month? →
Comparing it with its sector does not say whether it is a good buy: this is not investment advice.
Score by category
0 to 10 · hover overtap each one to see what it measuresKey metrics
at the analysis date · compared with the Healthcare medianValuation
- Forward P/E
- 2,301.0
- EV / EBITDA
- −33.1
- Price / book
- −5.2
- Price / sales
- 18.2
- Market cap
- 13.0B USD
- Enterprise value
- 15.7B USD
Profitability
- ROA
- −26.0%
- Gross margin
- 94.4%
- Operating margin
- −43.9%
- Net margin
- −97.0%
- Free cash flow
- −320.3M USD
- FCF yield
- −2.5%
Solvency
- Total debt
- 3.4B USD
- Net debt
- 2.7B USD
- Cash
- 720.2M USD
- EBITDA
- −472.8M USD
- Net debt / EBITDA
- −5.61
- Current ratio
- 1.23
- Quick ratio
- 1.09
Growth
- Revenue growth
- +120.4%
- EPS (TTM)
- −3.56 USD
- EPS (forward)
- 0.03 USD
Dividend
- Dividend yield
- 0.0%
Risk and market
- Beta
- 0.97
- Analyst consensus
- Strong buy (21)
- Target price
- 109.05 USD
- 52-week range
- 52.75 – 93.42
Recent news
All BBIO news →Compare it with its sector
All 217 in Healthcare →Frequently asked questions about BridgeBio Pharma
Is BridgeBio Pharma stock cheap or expensive?
On Price / sales, it trades 434% above the Healthcare median. Valuation score: 0.6 out of 10 (median for Healthcare: 4.7). Average analyst target: 109.05 USD, +64.0% versus the price. This is not investment advice.
What score does BridgeBio Pharma get on MeridIAn Screener?
It scores 5.8 out of 10, rank 1,132 of 2,130 (better than 43% of the companies analysed). Its strongest category is Growth (10.0) and its weakest, Dividend (0.5). Analysis of 08/10/2026.
How much is BridgeBio Pharma worth on the stock market?
Its market capitalisation is 13.0B USD and its enterprise value, debt included, is 15.7B USD.
How much debt does BridgeBio Pharma have?
Its net debt (debt minus cash) is 2.7B USD.
Does BridgeBio Pharma pay a dividend?
It pays no dividend, or almost none.
How has BridgeBio Pharma stock performed over the last year?
It has risen 19.8% over the last year, excluding dividends. Over the last 52 weeks it has traded between 52.75 and 93.42 USD. Past performance does not guarantee future results.
What do analysts think of BridgeBio Pharma?
21 analysts cover it; their average recommendation is “Strong buy” and their average target is 109.05 USD (+64.0% versus the price). It is an estimate, not market data.